ERBB2 and breast carcinoma: As HER2 amplicon genes are part of the 21 gene panel used in determining the Oncotype Dx recurrence score (RS), breast cancers with HER2 amplification generally have high RS, high histological grade, and a high genomic grade and are easily and correctly identified as poor prognosis by the assay.